HARVARD BIOSCIENCE, INC. Revenue
HARVARD BIOSCIENCE, INC. (HBIO) reported Revenue of $22.73 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-11
- HARVARD BIOSCIENCE, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $22.73M, a 11.13% increase year-over-year.
- HARVARD BIOSCIENCE, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $20.75M, a 4.68% decline year-over-year.
- HARVARD BIOSCIENCE, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $23.73M, a 3.34% decline year-over-year.
- HARVARD BIOSCIENCE, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $20.59M, a 6.28% decline year-over-year.
- HARVARD BIOSCIENCE, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $86.55M, a 8.06% decline from fiscal 2024.
- HARVARD BIOSCIENCE, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $94.14M, a 16.14% decline from fiscal 2023.
- HARVARD BIOSCIENCE, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $112.25M, a 0.96% decline from fiscal 2022.
- HARVARD BIOSCIENCE, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $113.33M, a 4.68% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $22.73M 10-Q · filed 2026-08-11 | $43.48M 10-Q · filed 2026-08-11 | $67.22M derived: sum of 3 quarters · filed 2026-08-11 | $87.81M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $20.75M 10-Q · filed 2026-05-12 | $44.49M derived: sum of 2 quarters · filed 2026-05-12 | $65.08M derived: sum of 3 quarters · filed 2026-05-12 | $85.53M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $23.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $44.33M derived: sum of 2 quarters · filed 2026-03-13 | $64.78M derived: sum of 3 quarters · filed 2026-08-11 | $86.55M 10-K · filed 2026-03-13 | |
| 2025-09-30 | $20.59M 10-Q · filed 2025-11-06 | $41.04M derived: sum of 2 quarters · filed 2026-08-11 | $62.81M 10-Q · filed 2025-11-06 | $87.37M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $20.45M 10-Q · filed 2026-08-11 | $42.22M 10-Q · filed 2026-08-11 | $66.78M derived: sum of 3 quarters · filed 2026-08-11 | $88.75M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $21.77M 10-Q · filed 2026-05-12 | $46.33M derived: sum of 2 quarters · filed 2026-05-12 | $68.30M derived: sum of 3 quarters · filed 2026-05-12 | $91.40M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $24.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $46.53M derived: sum of 2 quarters · filed 2026-03-13 | $69.62M derived: sum of 3 quarters · filed 2026-03-13 | $94.14M 10-K · filed 2026-03-13 | |
| 2024-09-30 | $21.97M 10-Q · filed 2025-11-06 | $21.97M 10-Q · filed 2024-11-08 | $45.07M derived: sum of 2 quarters · filed 2025-11-06 | $69.58M 10-Q · filed 2025-11-06 | $97.73M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $23.10M 10-Q · filed 2025-08-11 | $47.61M 10-Q · filed 2025-08-11 | $75.76M derived: sum of 3 quarters · filed 2025-08-11 | $101.13M derived: sum of 4 quarters · filed 2025-08-11 | |
| 2024-03-31 | $24.51M 10-Q · filed 2025-05-12 | $52.66M derived: sum of 2 quarters · filed 2025-05-12 | $78.03M derived: sum of 3 quarters · filed 2025-05-12 | $106.79M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | $28.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $53.52M derived: sum of 2 quarters · filed 2025-03-14 | $82.28M derived: sum of 3 quarters · filed 2025-03-14 | $112.25M 10-K · filed 2025-03-14 | |
| 2023-09-30 | $25.36M 10-Q · filed 2024-11-08 | $54.12M derived: sum of 2 quarters · filed 2024-11-08 | $84.10M 10-Q · filed 2024-11-08 | $112.52M derived: sum of 4 quarters · filed 2024-11-08 | |
| 2023-06-30 | $28.76M 10-Q · filed 2024-08-08 | $58.73M 10-Q · filed 2024-08-08 | $87.16M derived: sum of 3 quarters · filed 2024-08-08 | $114.08M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $29.98M 10-Q · filed 2024-05-07 | $58.40M derived: sum of 2 quarters · filed 2024-05-07 | $85.32M derived: sum of 3 quarters · filed 2024-05-07 | $114.53M derived: sum of 4 quarters · filed 2024-05-07 | |
| 2022-12-31 | $28.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $55.35M derived: sum of 2 quarters · filed 2024-03-07 | $84.56M derived: sum of 3 quarters · filed 2024-03-07 | $113.33M 10-K · filed 2024-03-07 | |
| 2022-09-30 | $26.92M 10-Q · filed 2023-11-07 | $56.13M derived: sum of 2 quarters · filed 2023-11-07 | $84.91M 10-Q · filed 2023-11-07 | $117.96M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | $29.21M 10-Q · filed 2023-08-08 | $57.99M 10-Q · filed 2023-08-08 | $91.04M derived: sum of 3 quarters · filed 2023-08-08 | $120.70M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | $28.78M 10-Q · filed 2023-04-26 | $61.83M derived: sum of 2 quarters · filed 2023-04-26 | $91.50M derived: sum of 3 quarters · filed 2023-04-26 | $120.69M derived: sum of 4 quarters · filed 2023-04-26 | |
| 2021-12-31 | $33.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $62.72M derived: sum of 2 quarters · filed 2023-03-09 | $91.92M derived: sum of 3 quarters · filed 2023-03-09 | $118.90M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $29.66M 10-Q · filed 2022-11-09 | $58.86M derived: sum of 2 quarters · filed 2022-11-09 | $85.85M 10-Q · filed 2022-11-09 | $116.83M derived: sum of 4 quarters · filed 2022-11-09 | |
| 2021-06-30 | $29.20M 10-Q · filed 2022-08-04 | $56.19M 10-Q · filed 2022-08-04 | $87.17M derived: sum of 3 quarters · filed 2022-08-04 | $111.21M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | $26.99M 10-Q · filed 2022-05-04 | $57.97M derived: sum of 2 quarters · filed 2022-05-04 | $82.01M derived: sum of 3 quarters · filed 2022-05-04 | $105.32M derived: sum of 4 quarters · filed 2022-05-04 | |
| 2020-12-31 | $30.98M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $55.02M derived: sum of 2 quarters · filed 2022-03-11 | $78.33M derived: sum of 3 quarters · filed 2022-03-11 | $102.10M 10-K · filed 2022-03-11 | |
| 2020-09-30 | $24.04M 10-Q · filed 2021-11-05 | $47.34M derived: sum of 2 quarters · filed 2021-11-05 | $71.12M 10-Q · filed 2021-11-05 | $102.09M derived: sum of 4 quarters · filed 2021-11-05 | |
| 2020-06-30 | $23.31M 10-Q · filed 2021-08-06 | $47.08M 10-Q · filed 2021-08-06 | $78.05M derived: sum of 3 quarters · filed 2021-08-06 | $105.47M derived: sum of 4 quarters · filed 2021-08-06 | |
| 2020-03-31 | $23.77M 10-Q · filed 2021-05-07 | $54.74M derived: sum of 2 quarters · filed 2021-05-07 | $82.16M derived: sum of 3 quarters · filed 2021-05-07 | $111.75M derived: sum of 4 quarters · filed 2021-05-07 | |
| 2019-12-31 | $30.97M 10-K · filed 2020-03-16 | $58.39M derived: sum of 2 quarters · filed 2020-11-06 | $87.97M derived: sum of 3 quarters · filed 2020-11-06 | $116.18M 10-K/A · filed 2021-03-17 | |
| 2019-09-30 | $27.42M 10-Q · filed 2020-11-06 | $57.00M derived: sum of 2 quarters · filed 2020-11-06 | $85.20M 10-Q · filed 2020-11-06 | $119.06M derived: sum of 4 quarters · filed 2020-11-06 | |
| 2019-06-30 | $29.58M 10-Q · filed 2020-08-10 | $57.79M 10-Q · filed 2020-08-10 | $91.64M derived: sum of 3 quarters · filed 2020-08-10 | $120.28M derived: sum of 4 quarters · filed 2020-08-10 | |
| 2019-03-31 | $28.20M 10-Q · filed 2020-05-08 | $62.06M derived: sum of 2 quarters · filed 2020-05-08 | $90.69M derived: sum of 3 quarters · filed 2020-05-08 | $122.22M derived: sum of 4 quarters · filed 2020-05-08 | |
| 2018-12-31 | $33.86M 10-K · filed 2020-03-16 | $62.49M derived: sum of 2 quarters · filed 2020-03-16 | $94.02M derived: sum of 3 quarters · filed 2020-03-16 | $120.77M 10-K · filed 2020-03-16 | |
| 2018-09-30 | $28.64M 10-K · filed 2020-03-16 | $60.16M derived: sum of 2 quarters · filed 2020-03-16 | $86.92M derived: sum of 3 quarters · filed 2020-03-16 | ||
| 2018-06-30 | $31.52M 10-K · filed 2020-03-16 | $58.28M derived: sum of 2 quarters · filed 2020-03-16 | |||
| 2018-03-31 | $26.76M 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |